A5068346090- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Transplantation: Methods and Outcomes
- Renal Diseases and Glomerulopathies
- Complement system in diseases
- Blood groups and transfusion
- Organ and Tissue Transplantation Research
- Polyomavirus and related diseases
- Pregnancy and Medication Impact
- Multiple Myeloma Research and Treatments
- Organ Donation and Transplantation
- T-cell and B-cell Immunology
- Neurological Complications and Syndromes
- Systemic Lupus Erythematosus Research
- Cytomegalovirus and herpesvirus research
- Immunodeficiency and Autoimmune Disorders
- Platelet Disorders and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Diabetes and associated disorders
- Immune Cell Function and Interaction
- Parvovirus B19 Infection Studies
- Clinical Nutrition and Gastroenterology
- Liver Disease and Transplantation
- Renal and Vascular Pathologies
- HIV/AIDS drug development and treatment
Hansa Biopharma (Sweden)
2023
Terasaki Foundation
2012-2021
University of California, Los Angeles
2015-2016
Development Fund
2016
Symbiosis International University
2015
University of Iowa
2015
Cedars-Sinai Medical Center
2015
National Cancer Institute
2015
Orthopaedic Research Foundation
2015
Cancer Prevention Institute of California
2015
Background. Current antihumoral therapies in transplantation and autoimmune disease do not target the mature antibody-producing plasma cell. Bortezomib is a first class proteosomal inhibitor, that Food Drug Administration approved, for treatment of cell-derived tumors multiple myeloma. We report clinical experience with cell-targeted therapy (bortezomib) as an antirejection strategy. Methods. Eight episodes mixed antibody-mediated rejection (AMR) acute cellular (ACR) six transplant...
To date, limited information is available describing the incidence and impact of de novo donor-specific anti-human leukocyte antigen (HLA) antibodies (dnDSA) in primary renal transplant patient. This report details dnDSA actual 3-year post-dnDSA graft outcomes.The study includes 189 consecutive nonsensitized, non-HLA-identical patients who received a kidney between March 1999 2006. Protocol testing for DSA via LABScreen single beads (One Lambda) was done before transplantation at 1, 3, 6, 9,...
Evidence shows posttransplant antibodies lead to renal allograft failure, but does the time elapsed between transplantation and antibody development impact survival? This is first study showing importance of when appear.Serial sera were collected during 17 years (1991-2008) from two groups patients, one whose failed due chronic rejection containing 25 patients (230 sera) a control group consisting graft functioning (305 who matched by transplant date patient failed.The median follow-up for...
Anti-HLA-DQ antibodies are the predominant HLA class II donor-specific (DSAs) after transplantation. Recently, de novo DQ DSA has been associated with worse allograft outcomes. The aim of this study was to determine further complement-binding characteristics most harmful DSA.Single-antigen bead technology used screen 284 primary kidney transplant recipients for presence posttransplantation DSA. Peak sera 34 only and 20 plus other DSAs were analyzed by a modified single-antigen assay using...
Current treatments for autoantibody-mediated diseases (i.e., systemic lupus erythematosus) and alloantibodies (in transplant) are minimally effective. Although they deplete naïve B cells, plasmablasts, transiently reduce antibody concentrations, effective against long-lived, antibody-producing plasma cells. In transplantation, cells produce antibodies directed human leukocyte antigen (HLA) antigens causing poor allograft survival. We report the first clinical experience with a cell depleting...
Long-term clinical outcome of islet transplantation is hampered by the rejection and recurrence autoimmunity. Accurate monitoring may allow for early detection treatment these potentially compromising immune events. Islet transplant was analyzed in 59 consecutive pancreatic recipients whom baseline de novo posttransplant autoantibodies (GAD antibody, insulinoma-associated protein 2 antigen, zinc transporter type 8 antigen) donor-specific alloantibodies (DSA) were quantified. Thirty-nine...
De novo donor-specific antibody (dnDSA) is associated with antibody-mediated rejection (AMR) and allograft loss, yet the histology dnDSA remains unclear. The aim of this study was to examine in patients serial surveillance biopsies. We retrospectively studied adult conventional solitary kidney transplant recipients from October 2007 May 2014. definition new (DSA) mean fluorescence intensity (MFI) >1000. incidence 7.0% (54 771) over follow-up 4.2 ± 1.9 years. Patients had reduced...
Although modifications of gut microbiota with antibiotics (Abx) influence mouse skin and cardiac allografts, its role in orthotopic liver transplantation (OLT) remains unknown. We aimed to determine whether how recipient Abx pretreatment may affect hepatic ischemia-reperfusion injury (IRI) OLT outcomes. Mice (C57BL/6) or without treatment (10 days) were transplanted allogeneic (BALB/c) cold-stored (18 hours) livers, followed by blood sampling (6 hours). divided 264 human recipients on the...
The ITR serves as an international database for centers around the world to contribute current knowledge about intestinal transplant outcomes. Led by IRTA and managed Terasaki Research Institute, collects data annually uses these generate reports that guide management strategies policy statements. aim of this manuscript was analyze outcomes specific pediatric transplantation. Outcome children transplanted from 1985 2017 were analyzed predictive factors assessed. A total 2010 received 2080...
With standard IgG donor-specific anti-HLA antibody (DSA) testing, it is unclear which immunoglobulin-G (IgG) DSA positive patients will fail. We looked further into the immune response by studying immunoglobulin-M (IgM) and subclass 3 (IgG3) to determine if these identify at highest risk for allograft loss.In 189 consecutively transplanted primary renal recipients, sera were collected sequentially pre- posttransplant. Of 189, 179 had available retrospectively test IgG, IgM, IgG3 antibodies...
In Brief Background Rejection remains the leading cause of allograft loss, and a major barrier to improving long-term outcomes after intestinal transplantation. Our aim is define prevalence investigate role donor-specific antibody (DSA) on graft outcomes. Methods The study includes 109 transplants performed in 95 recipients at single center. Patients were screened for DSA pretransplant, monitored regularly posttransplant when clinically indicated using single-antigen bead Luminex assay....
Background. Chronic antibody-mediated rejection (cAMR) results in the majority of renal allograft losses. Currently, there are no approved therapies. We recently reported on clinical use tocilizumab (TCZ) for treatment cAMR HLA-sensitized kidney transplant patients. IgG 1 and 3 subclasses potent effectors complement- antibody-dependent cellular cytotoxicity, which critical mediators AMR. Here, we examined impact TCZ total IgG, 1-4 subclasses, anti–HLA-IgG (total subclasses). Methods....
The development of anti-donor humoral responses after transplantation associates with higher risks for acute rejection and 1-year graft survival in adults, but the influence immunity on transplant outcomes children is not well understood. Here, we studied evolution low-risk pediatric patients during first 2 years renal transplantation. Using data from 130 randomized to steroid-free (SF) or steroid-based (SB) immunosuppression NIH-SNSO1 trial, correlated presence serum anti-HLA antibodies...
The development of human leukocyte antigen (HLA) donor‐specific antibody/antibodies (DSA) is not well described in liver transplant (LT) patients undergoing immunosuppression (IS) withdrawal protocols despite the allograft risk associated with de novo DSA (dnDSA). We analyzed dnDSA 69 LT who received calcineurin inhibitor monotherapy and were enrolled ITN030ST study. Of these patients, 40 stable randomized to IS maintenance (n = 9) or minimization 31). Nine 31 achieved complete free IS....
We aimed to determine the long-term outcomes of eculizumab-treated, positive crossmatch (+XM) kidney transplant recipients compared with +XM and age-matched negative (−XM) controls. performed an observational retrospective study examined allograft survival, histologic findings, B-cell flow cytometric XM (BFXM), allograft-loss–associated factors. The mean (SD) posttransplant follow-up was 6.3 (2.5) years in eculizumab group; 7.6 (3.5), control 7.9 (2.5), −XM group. overall death-censored...
The common endpoint in the treatment of antibody-mediated rejection (AMR) is functional reversal (creatinine levels). Reduction human leukocyte antigen (HLA) antibody strength not commonly considered as an essential for AMR resolution. purpose this study was to determine whether reduction HLA intensity patients with histologic influences long-term renal allograft survival.Renal recipients were included if he or she had a biopsy diagnosis (between August 2000 and October 2008) serial...
Evidence of the short-term effect bortezomib on donor-specific human leukocyte antigen (HLA) antibody (DSA) removal capacity has emerged. However, no published data characterize durability DSA response. Here, we report long-term response results renal transplant patients treated with bortezomib.In this single-center study, 26 living-donor a positive level de novo were preemptively (1.3 mg/m × 4 doses). A total 15 received as part combination regimen; 11 alone. Weekly serial measurements HLA...